Paper39743545
The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors.
Li R and 13 others. Cell Discov, 2025. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors. Papers, record 39743545. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39743545
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20498667 | Cross-priming in health and disease. | Nat Rev Immunol | 2010 | https://conductscience.org/library/papers/20498667 | PubMed |
| 2 | 36604431 | Neoantigens: promising targets for cancer therapy. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36604431 | PubMed |
| 3 | 11231627 | Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. | Nat Med | 2001 | https://conductscience.org/library/papers/11231627 | PubMed |
| 4 | 19132916 | T cell activation. | Annu Rev Immunol | 2009 | https://conductscience.org/library/papers/19132916 | PubMed |
| 5 | 30089911 | Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. | Nature | 2018 | https://conductscience.org/library/papers/30089911 | PubMed |
| 6 | 28775780 | Treatment of Neuroblastoma with an Engineered "Obligate" Anaerobic Salmonella typhimurium Strain YB1. | J Cancer | 2017 | https://conductscience.org/library/papers/28775780 | PubMed |
| 7 | 22666539 | Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain. | Sci Rep | 2012 | https://conductscience.org/library/papers/22666539 | PubMed |
| 8 | 23890059 | Oncology meets immunology: the cancer-immunity cycle. | Immunity | 2013 | https://conductscience.org/library/papers/23890059 | PubMed |
| 9 | 28263959 | Salmon provides fast and bias-aware quantification of transcript expression. | Nat Methods | 2017 | https://conductscience.org/library/papers/28263959 | PubMed |
| 10 | 29141660 | xCell: digitally portraying the tissue cellular heterogeneity landscape. | Genome Biol | 2017 | https://conductscience.org/library/papers/29141660 | PubMed |
| 11 | 35603308 | Advances in oncolytic virotherapy. | Commun Med (Lond) | 2022 | https://conductscience.org/library/papers/35603308 | PubMed |
| 12 | 8917636 | Direct transfer of a foreign MHC gene into human melanoma alters T cell receptor V beta usage by tumor-infiltrating lymphocytes. | Cancer Immunol Immunother | 1996 | https://conductscience.org/library/papers/8917636 | PubMed |
| 13 | 30413827 | Cytokines in clinical cancer immunotherapy. | Br J Cancer | 2019 | https://conductscience.org/library/papers/30413827 | PubMed |
| 14 | 8506311 | Immunotherapy of malignancy by in vivo gene transfer into tumors. | Proc Natl Acad Sci U S A | 1993 | https://conductscience.org/library/papers/8506311 | PubMed |
| 15 | 22781695 | Oncolytic virotherapy. | Nat Biotechnol | 2012 | https://conductscience.org/library/papers/22781695 | PubMed |
| 16 | 38278784 | Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice. | Nat Commun | 2024 | https://conductscience.org/library/papers/38278784 | PubMed |
| 17 | 35835409 | Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. | Cancer Lett | 2022 | https://conductscience.org/library/papers/35835409 | PubMed |
| 18 | 35401745 | Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy. | J Oncol | 2022 | https://conductscience.org/library/papers/35401745 | PubMed |
| 19 | 34557778 | clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. | Innovation (Camb) | 2021 | https://conductscience.org/library/papers/34557778 | PubMed |
| 20 | 22658128 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658128 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42844249 | Bioengineering strategies for improving the immunogenicity of mRNA vaccines. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42844249 | PubMed |
| 42783445 | COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42783445 | PubMed |
| 42198337 | Delivery of mRNA Therapeutics Beyond Infectious Diseases: Design Innovations and Applications in Oncology, Cardiovascular, and Rare Genetic Diseases. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198337 | PubMed |
| 42087213 | Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42087213 | PubMed |
| 42071000 | Harnessing pre-existing measles immunity: mRNA-Lipid nanoparticle-mediated measles hemagglutinin expression boosts antitumor CD8⁺ T cell responses. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42071000 | PubMed |
| 41180766 | EnteroMix and the emerging role of MRNA-based therapeutics in colorectal cancer: from preclinical tumor regression to clinical translation. | Ann Med Surg (Lond) | 2025 | https://conductscience.org/library/papers/41180766 | PubMed |
| 41002441 | Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. | Cells | 2025 | https://conductscience.org/library/papers/41002441 | PubMed |
| 40563598 | Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40563598 | PubMed |
| 40282336 | The Bright Future of mRNA as a Therapeutic Molecule. | Genes (Basel) | 2025 | https://conductscience.org/library/papers/40282336 | PubMed |
| 40269562 | The treatment of breast cancer in the era of precision medicine. | Cancer Biol Med | 2025 | https://conductscience.org/library/papers/40269562 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39743545
GET https://conductscience.org/api/papers/v1/39743545/references?page=2